Evidence map›Paper›PMID 40770349›Full record

ArticleExperimental hematology & oncology2025

Incidence, mortality, and risk factors of bladder, kidney, prostate and testicular cancers in China and comparisons with the United States, the United Kingdom, Japan, and the Republic of Korea: an up-to-date overview based on the Global Burden of Disease 2021.

Gaohaer Kadeerhan, Zhongji Jiang, Hong Guo, Xinzhi Ma, Jin Zhang, Wenmin Guo, Jiedong Jia, Yibo Gao, Dongwen Wang

Abstract read
In one paragraph

Article in Experimental hematology & oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gaohaer KadeerhanCentral Laboratory & Shenzhen Key Laboratory of Epigenetics and Precision Medicine for Cancers, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.
Zhongji JiangDepartment of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.
Hong GuoFirst College of Clinical Medicine, Shanxi Medical University, Taiyuan, Shanxi, 030001, China.
Xinzhi MaCentral Laboratory & Shenzhen Key Laboratory of Epigenetics and Precision Medicine for Cancers, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.
Jin ZhangFirst College of Clinical Medicine, Shanxi Medical University, Taiyuan, Shanxi, 030001, China.
Wenmin GuoDepartment of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.
Jiedong JiaDepartment of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China.
Yibo GaoCentral Laboratory & Shenzhen Key Laboratory of Epigenetics and Precision Medicine for Cancers, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. gaoyibo@cicams.ac.cn.
Dongwen WangDepartment of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, 518116, China. urology2007@126.com.

Funding

Cooperation Fund of CHCAMS and SZCH CFA202201001, SZ2020ZD001Sanming Project of Medicine in Shenzhen No.SZSM202311002, No.SZSM202111003Shenzhen Science and Technology Program ZDSYS20220606101604009
6 · The paper itself

Abstract

backgroundThe burden of genitourinary cancers has significantly changed in China over the recent decades. This study aims to identify the epidemiological trends and disparities in four common genitourinary cancers, including bladder, kidney, prostate, and testicular cancers, to inform public health strategies and interventions.

methodsBased on the Global Burden of Disease Study 2021, we examined incident cases, mortality, age-standardized incidence rates (ASIRs), age-standardized mortality rates (ASMRs), mortality-to-incidence ratios (MIRs), and risk factors for four genitourinary cancers globally and in the East Asia and Pacific, China, Japan, the Republic of Korea, the United States, and the United Kingdom from 1990 to 2021 across four specified age groups: 0-14, 15-49, 50-74, and ≥ 75 years. Trend analysis was conducted using Joinpoint analysis to calculate the average annual percentage changes (AAPCs). Decomposition analysis was performed to identify the population-level factors contributing to these trends.

resultsIn 2021, China reported approximately 266,887 incident cases and 108,589 deaths from genitourinary cancers, exhibiting distinct age-related patterns. ASIRs for male kidney cancer among those aged 0-14 years and testicular cancer among those aged ≥ 75 years, as well as ASMRs for male bladder cancer aged 15-49 years and testicular cancer aged ≥ 75 years, were higher in China than in the studied regions and countries. The MIRs for genitourinary cancers were generally higher in China. From 1990 to 2021, a notable increase in ASIRs for genitourinary cancers in both sexes, as well as ASMRs for male kidney and prostate cancers, across age groups ranging from 15 to 49 years to ≥ 75 years was observed in China, accompanied by higher AAPCs. The decomposition analysis identified the key population-level contributors to the incidence and mortality trends of genitourinary cancers, highlighting the varying influences of aging, population growth, and epidemiological changes. Smoking-related genitourinary cancer deaths remained high in Chinese males, and mortality related to high body mass index for kidney cancer and elevated fasting plasma glucose levels for bladder cancer also increased.

conclusionsThe distinct age-specific patterns, elevated rates within specific age groups, and marked upward temporal trends of genitourinary cancers in China underscore the critical need for targeted, age-stratified public health interventions.

Indexed as

Bladder cancerIncidenceKidney cancerMortalityProstate cancerRisk factorTesticular cancer

Identifiers

PMID40770349
PMCPMC12329898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.